Objectives: This study aims to determine the effects of oral glucosamine on glucose metabolism and insulin resistance in non-diabetic patients with osteoarthritis in Northeastern Iran.
Osteoarthritis (OA) is a very common disease in the elderly, affecting approximately 40% of patients older than 60 years of age. 1 Analgesics and non-steroidal antiinflammatory drugs are conventional therapies in this regard, although with certain adverse effects. Popular and widelyused, glucosamines are currently administered for treating OA worldwide. On the other hand, type II diabetes mellitus is also more prevalent in this age population. In individuals aged over 50, OA may be concurrent with diabetes in 10-15% of the cases. 2, 3 Glucosamine may play a role in glucose metabolism, which has raised concerns about its safety profile in diabetic patients. The entry of glucosamine into cells is stimulated by insulin and involves the glucose-transporter system. Glucosamine is then phosphorylated to glucosamine-6 phosphate by tissue hexokinases. 4 Several animal and in vitro studies have shown that high doses of glucosamine can induce insulin resistance and raise plasma level of glucose. [5] [6] [7] [8] However, other human studies having investigated shortterm intravenous glucosamine infusion effects did not report any such adverse impacts on either insulin sensitivity or glucose level. 9, 10 Few studies aiming to evaluate the effects of oral standard doses of glucosamine in healthy humans concluded that oral glucosamine did not induce insulin resistance, [11] [12] [13] these findings add fuel to the controversy of whether glucosamine can adversely affect glucose metabolism. In this study, we aimed to determine the effects of oral glucosamine on glucose metabolism and insulin resistance in non-diabetic patients with OA in Northeastern Iran. 14, 15 Patients, either diagnosed with diabetes, or with a family history of diabetes, body mass index <20 and >30 kg/m 2 ), history of liver or renal disease, myocardial infarction, inflammatory diseases, pregnancy or lactation, systemic diseases that induce insulin resistance and those taking drugs that interfere in glucose metabolism including anticonvulsants, glucocorticoids and antipsychotics, were excluded. Thirteen patients were excluded on the grounds that they either subsequently declined or failed to meet our inclusion criteria. The remaining 50 patients (18 males, 32 females, mean age 63.9±6.86 years; range 50 to 79 years) were divided into two equal groups in a blind manner by computerized randomization. Both observers and the patients were blind as to the type of randomization and the drug form. After drawing serum baselines, first group received the usual dose of 1500 mg (500 mg x 3 capsules daily) glucosamine sulfate (Heaith Burst Company, Ohio, USA) for 90 days, whereas the second group received placebo capsules containing cellulose. Both groups were allowed to use analgesic medications, which they had taken before as needed. Every month, based on a random number chart, patients received boxes of 90 capsules of glucosamine or placebo from the dispenser in our center for three months and we ensured that the capsules were used fully and properly. After 90 days, laboratory tests were repeated in all patients. We excluded five patients in each group as they failed to take the drug or did not refer for follow-up. Finally, the study was completed with 40 patients (15 males, 25 females, mean age 63.8±7.64 years; range 49 to 80 years) with non-diabetic OA and body mass index within the medium range.
PATIENTS AND METHODS
Participants were informed about the potential side effects of glucosamine including abdominal discomfort, diarrhea, constipation and rising in blood glucose, lipid profiles and blood pressure. All patients gave informed consent for participation in the study. The study protocol was approved by the Ethics Committee of Mashhad University of medical sciences. This Following a thorough medical history as well as physical examination, baseline serum fasting blood sugar and insulin levels were measured for each subject, using glucose oxidase method (Human GmbH, Wiesbaden, Germany) and immunoradiometric assay with intra-assay coefficient of variation of 4.3% and inter-assay of 3.4%, respectively. Then, patients underwent glucose tolerance test with 75 grams of glucose with blood glucose measured two hours later. Insulin resistance (Homeostasis Model Assessmentof Insulin Resistance=HOMA-IR 16 ) was calculated as follows:
Statistical analysis
Laboratory results before and after the intervention were compared with paired student's t-test for normal distributed data. Wilcoxon signedrank test was used for the comparison of not normally distributed data. P-values less than 0.05 were considered significant. Consolidated standards of reporting trials flow diagram of the study is shown in Figure 1 .
RESULTS
The two groups were similar in terms of mean age and sex distribution (Figure 2 ). The mean ages in the glucosamine and placebo groups were 63.4±7.74 years and 64.9±8.46 years, respectively, with no significant difference between the two (p=0.44). Females constituted 65% and 60% of the glucosamine and placebo groups, respectively (p=0.74).
There were no significant differences between the two groups regarding the levels of fasting blood sugar, insulin, HOMA-IR, and blood sugar after 75 grams load of glucose. There were no significant changes in the laboratory results after 90 days of intervention (Table 1 ). In the glucosamine group, there were no significant changes in fasting blood sugar (94.1±7.14 mg/dL versus 93.5±9.45 mg/dL, p=0.15), glucose tolerance test (99.3±8.99 mg/dL versus 103.3±10.1 mg/dL, p=0.07), and homeostatic model assessmentinsulin resistance (1.57±0.21 versus 1.48±0.21, p=0.13) after treatment. Blood sugar, two hours after the consumption of 75 grams of glucose, increased slightly in the glucosamine group which was considered insignificant. Also, placebo did not significantly affect serum glucose levels and insulin resistance.
DISCUSSION
Osteoarthritis, a chronic degenerative disease, is considered to be one of the main causes of disability in the elderly population. Use of glucosamine, which is frequently prescribed for treating OA, is still plagued with heated controversies regarding the potential effects on glucose metabolism. 17, 18 The effect of glucosamine on blood glucose and insulin sensitivity may be attributed to the inverse flux in the hexosamine pathway. 19 Several experimental studies have been conducted to determine how it may affect glucose metabolism. [4] [5] [6] [7] These studies indicate high concentrations achieved via intravenous injection, which might impair insulin sensitivity and glucose tolerance. In a randomized-placebo controlled study, Monauni et al. 10 concluded that high doses of glucosamine were in association with glucose tolerance impairments following intravenous glucose tolerance test. The authors concluded that this result was possibly due to the effect of glucose inhibiting pancreatic glucokinase. Also, some investigators believe that glucosamine may affect serum glucose levels and insulin resistance at doses used to treat OA. 20.21 On the other hand, several studies, including ours, indicate that usual doses of oral glucosamine have no significant effect on glucose metabolism. Our study was conducted in individuals with medium range of body mass index who suffered from OA and took oral glucosamine 1500 mg/day for 12 weeks. Similarly, Muniyappa et al. 3 investigated the effects following the administration of 1500 mg/day oral glucosamine with regard to insulin sensitivity and fasting blood glucose in both lean and obese patients, with no tangible alteration in plasma as well as glucose insulin levels in either group after six weeks. Other studies [22] [23] [24] [25] in diabetic patients showed that the administration of glucosamine 1500 mg/day had no significant effect on diabetes related endpoints, concluding that glucosamine, at usual doses, does not have any adverse effect on glycemic control in diabetic patients.
In a review of 33 studies of oral glucosamine administration for an average of 17 weeks on 3,063 subjects, Anderson et al. 26 concluded that there were no adverse effects on blood, urine or fecal parameters, neither any effect on glucose metabolism. Finally, a systematic review by Dostrovsky et al. 27 demonstrated that clinical evidence regarding the effects of oral glucosamine on glucose metabolism does not seem consistent; thus further research should be warranted in this issue.
Given the disparity of the findings in this respect, we decided to conduct our clinical trial in a different area with rather different immunogenic background of patients with OA. Although most of our patients with OA receiving glucosamine reported partial relief of their symptoms, we did not aim to assess the efficacy of the drug in this study.
Inconsistent results in the previous studies may be attributed to their varying dosages, route and duration of glucosamine administration, and the heterogeneity in the state of glucose condition in patients with diabetes, impaired glucose metabolism, and normoglycemic conditions. A limitation of this study was the use of the HOMA-IR model for assessment of insulin resistance. Although the glucose clamping technique is considered the gold standard for assessing insulin resistance, a close correlation between HOMA-IR and glucose clamping was shown in their estimation of insulin resistance. 28 Another limiting factor was the relatively small sample size which limited the statistical results of our study.
In conclusion, oral glucosamine, when prescribed in routine doses in non-diabetic patients with OA, had no significant effect on blood glucose and insulin resistance. Further long-term studies using larger sample sizes with diabetic and non-diabetic patients with OA may shed more light on the topic. 
